Halloran Speaker Series | The Regulatory Wrap: Considerations Towards a Successful IND Submission
Despite the COVID-19 pandemic, the biotech and pharmaceutical industry has not slowed down innovation or stifled the desire to impact human health with new potential life-saving therapies. Over the past year, Halloran has submitted 18 INDs and supported 34 formal FDA meetings. 2020 may have been one of the busiest years to date for regulatory activity with 2021 following in its footsteps.
Given our deep regulatory expertise and the number of INDs we have submitted, our regulatory consultants will present and discuss considerations, common pitfalls, and assumptions they see their clients make, and their recommended approaches towards a successful IND submission.
Please join us as a group of esteemed Halloran women lead the conversation on Wednesday, April 14th from 2:00-3:00 p.m. EST.